AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

USA: The management of fracture-related infections (FRIs) often involves prolonged antibiotic therapy, with intravenous (IV) ...

A newlywed Baltimore Ravens Marching Band member from Hagerstown is facing a life-threatening battle with a severe blood ...

The treatment of hospitalized patients with community-acquired pneumonia has traditionally been with intravenous antibiotics. The administration of intravenous antibiotics for community-acquired ...

Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and ...

could safely shorten the time children spend on intravenous (IV) antibiotics in hospitals. Despite promising previous analysis, the study, found that using the PCT biomarker to guide treatment ...

Our study, involving 61 immunocompentent patients with primary vertebral osteomyelitis, illustrates that switching to an oral antibiotic regimen after 2 weeks of intravenous therapy may be safe ...

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...